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ABSTRACT

Pharmacologic doses of growth hormone (HGH) or chronic HGH
excess induce glucose intolerance and insulin resistance.

Whether

acute increments of HGH are diabetogenic as well, is not established.
In fact, HGH is reported to have acute insulin-like effects.

In this

study, 8 postabsorptive normal subjects randomly received a HGH
(3pg/kg/hr) or saline infusion for 8 hours.

After 5 hours, a 100 gram

oral glucose tolerance test (OGTT) was performed and HGH or saline was
continued for the remaining 3 hours.

Insulin binding to erythrocytes

and monocytes was measured before and 4 hours after HGH infusion.
Plasma HGH during HGH infusion rose to 25-35 ng/rnl.

Before OGTT, plasma

glucose remained unchanged (85±2 mg/dl vs 86±2 at 5 hours), FFA
increased by 50% (p<0.01) and ketones increased by 86% (p<0.01), despite
35% greater fasting plasma insulin levels in the HGH-infused subjects
(p<0.005).

Fasting plasma alanine decreased by 22% (p<0.005) during HGH

infusion whereas the concentration^. of other amino acids remained
unchanged.

After OGTT, HGH-infused subjects exhibited a marked deteriora¬

tion in glucose tolerance.

Plasma glucose rose by 30-50 mg/dl (p<0.01)

above saline control values ( 2 hours, 162±12 mg/dl vs 121±7 and 3
hours, 124±13 vs 85±6) and the area under the glucose response curve
increased 2-fold (p<0.005).

This occurred in the face of 2-fold higher

insulin levels (peak values 168±33 yU/ml vs 85±26, p<0.005) in the
HGH-infused group.

Insulin binding to erythrocytes decreased by 16%

(p<0.01), whereas, insulin binding to monocytes increased by 45%.
Conclusions:

1) Acute physiologic elevations in HGH, which fail to

alter fasting plasma glucose, cause glucose intolerance and hyper-

insulinemia in man: 2) HGH-induced insulin resistance occurs in spite
of a rise in insulin binding to monocytes.

Our data suggest that HGH

has rapid-onset insulin antagonistic effects which might contribute
to glucose intolerance during stress.

INTRODUCTION

The metabolic consequences of stress in man frequently include
deterioration of glucose tolerance, protein wasting, enhanced
lipolysis and ketosis (1).

In addition, stress can provoke elevations

of one or more hormones, including epinephrine, glucagon, cortisol,
and growth hormone (2).

The roles of the first three of these hormones

in mediating stress hyperglycemia have recently been examined (3).
However, the significance of acute physiologic elevations of growth
hormone is not known.
The purpose of this thesis is to examine the effects of acute
physiologic increments in growth hormone levels on carbohydrate,
and protein metabolism.

fat,

As background information, the results of

previous studies in both man and animals will be reviewed.

First,

the regulation of growth hormone secretion and the growth hormone
response to stress will be discussed in order to establish the
magnitude and duration of the growth hormone response and the type
of situations in which this response might be expected to^occur.
Then the effect of chronic elevations of growth hormone, as seen in
acromegaly, will be considered.

Finally,

the effects of more acute

growth hormone elevations on fat, glucose and protein metabolism
will be summarized.

When considering this data,

it will be important

to remember that most of it derives from studies in which suprephysiologic concentrations of growth hormone were achieved.
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CH SECRETION
Growth hormone (GH) is a polypeptide secreted by the pituitary
in response to a variety of physiologic and psychologic stimuli.
Basal plasma levels in adults normally range between 1 to 5 ng/ml (A,5).
Bursts of GH secretion occur throughout the day.

The highest and most

consistent increases in GH are seen during stage III-IV sleep with peak
levels averaging 3A

t

6 ng/ml (6).

Basal GH concentrations have been reported to be slightly
higher in pre-menopausal women than in men or post-menopausal
women (7).

When the magnitude of the GH response to exercise,

arginine or insulin-induced hypoglycemia is compared at dif¬
ferent stages of the menstrual cycle, significantly higher
peak GH levels are found in the high estrogen phases of the cycle
than during menstruation (8-10).

Administration of estrogen but

not progesterone or testosterone to men also augments the peak GH
response to various stimuli (8,9).

Estrogens do not effect the

metabolic clearance rate, distribution space, or plasma half lire
of growth hormone (11).

They seem to work by increasing the

sensitivity of the pituitary to growth hormone releasing factor (12).
Regulation of GH secretion is closely tied to fluctuations
in plasma glucose concentrations.
stimulus of GH secretion.

Hypoglycemia is a potent

It is well documented that insulin-

induced hypoglycemia causes increments of 30 to 50 ng/ml in
plasma GH that persist for several hours (5,13-16).

Insulin

by itself does not mediate this response since administration of

glucose with insulin prevents GH increases (13).

Administration

of 2-deoxy-D-glucose, an inhibitor of intracellular glucose utili¬
zation, results in hyperglycemia but increased GH levels suggesting
that intracellular glucose concentration determines the GH re¬
sponse (14).

Conversely, glucose administration suppresses

plasma GH concentrations in normal subjects (5,13).

Results

of animal studies localize this response to glucose receptors in
the ventromedial nucleus of the hypothalamus (10).

These receptors

respond to absolute hypoglycemia, changing blood glucose con¬
centrations and intracellular deprivation of glucose (10).
Exercise induced augmentation of GH secretion has been re¬
ported by several groups (5,15,17).

GH has been shown to increase

during the first hour of walking on a treadmill to 43 ng/ml and
then to slowly decrease after that despite continuing exercise (17).
Although blood glucose levels did not change significantly during
this study, administration of glucose did suppress the exerciseinduced rise in GH (.17).
GH secretion is augmented in response to a variety of
physical stresses.

Several studies have documented a rise in GH

during surgery (15,18-21), the magnitude and duration of which is
proportional to the degree of surgical stress (22).

Patients

undergoing minor procedures (inguinal herniorrhaphy) generally
fail to exhibit GH elevations, whereas patients undergoing major
surgery (aortofemoral bypass) demonstrate peak intraoperative
GH levels of 20 to 30 ng/ml with elevated levels in blood lasting
up to eight days post-operation (22).

Other invasive procedures

that augment GH secretion include arterial catheterization (23)
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and cardiac catheterization (24).
Acute infectious diseases are associated with elevated
GH levels.

Injection of pseudomonas-derived polysaccharide

leads to peak GH levels of 26 ± 2 ng/ml at 2 hours (25-27).
This is not secondary to fever since injection of etiocholanolone, a pyrogen, does not augment GH secretion (27).

Additionally,

the increase in GH during injection of pseudomonas polysaccharide
is not suppresible by glucose (25).
also seen in viral illnesses.

Hypersecretion of GH is

Inoculation of normal subjects

with serum containing the sandfly fever virus results in peak GH
levels of 5 tu 12 ng/ml (28).

The rise in GH precedes the onset of

clinical symptoms by 7 to 14 hours and persists for several
days (28).
Diabetic ketoacidosis

(DKA) is another acute condition in

which elevated GH levels are frequently seen (7,29-31).

Unger (7)

found that in 5 patients with DKA, GH levels ranged from 1.0 to
70,0 ng/ml with the highest values seen in the most ketotic patients.
Cryer and Daughaday (29) described elevated GH levels, ranging from
13 to 215 ng/ml, in 7 of 12 patients with DKA.

They saw no

correlation between the magnitude of the GH response and the
clinical severity, degree of hyperglycemia or depression of serum
bicarbonate

However, they did not directly measure serum

ketones and try to correlate that with GH response.

Not all

studies have shown elevated pretreatment GH levels (32-33).
Instead, GH levels were seen to rise after initiation of treat¬
ment to levels ranging from 30 to 250 ng/ml and to remain elevated
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for at least 5 or 6 hours (29,32,33).
Elevation in GH levels are associated with more chronic
disease in man.

Patients with Laennec’s cirrhosis have

been shown to have abnormally high GH levels (34-36).
Hernandez et al„(35) found increased fasting GH levels, ranging
from 6.5 to 28 ng/ml, in 4 of 8 patients with cirrhosis.

Conn

and Daughaday (36) also reported elevated GH levels, ranging from
4 to 33 ng/ml,

in 14 of 18 patients.

Those patients with normal

GH valueshad clinically and chemically less advanced disease.
Similar results are seen in chronic renal failure (37-39).

For

example, Wright et al*{39) found GH elevated up to 60 ng/ml in
50 percent of their patients.

In both chronic liver and renal

disease, the abnormally high GH levels are partially due to a de¬
creased metabolic clearance rate and increased half life of the
hormone (11).

Additionally in liver disease hyperestrogenemia

iaig.-t potentiate secretion (12,35).

There is also evidence

that hypothalamic regulation is altered.

Paradoxical responses

frequently occur after standard provocative testing in patients
with chronic liver and kidney disease.

It has been reported that

GH increases after glucose administration (36-39) and fails to
rise after tolbutamide-induced hypoglycemia (40) in such patients.
Psychological stress is also associated with elevations in
GH.

Neurotic subjects showed significant increases in GH

during the mirror drawing test, a standard procedure for inducing
psychological stiess (41).

In another study, a medical student
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told that he had received an injection of a large amount of
insulin had an increase in GH by 1 hour to 10.5 ng/ml while
four students given the same saline injection but not told
that it contained insulin had no rise in GH (42).

Subjects

told that they were going to see a stressful movie also showed
significant increases in plasma GH (43).

Several studies support

the idea that elevations in GH in response to stress are re¬
lated more to the individuals type of defense mechanism than to
the particular type of stress and are independent of change in
the adrenocortical response (24,43-44).
The secretion of GH is ultimately regulated by stimuli
from the central nervous system.

There have been several recent

reviews detailing these interactions (4,10,45-46).

In brief,

pituitary synthesis and release of GH is under the control of the
hypothalamus.

Somatostatin has been shown to be the inhibitory

hypothalamic factor (47).

Although no hypothalamic stimulatory

substance has yet been isolated, there is convincing evidence that
one exists (12),

In humans,

the hypothalamus is thought to exert

a predominantly stimulatory effect since hypothalamic lesions or
section of the pituitary stalk result in lower basal GH levels
and decreased GH response to hypoglycemia, arginine, and L-DOPA
(4,45-46).

Augmentation of GH secretion in response to insulin-

hypoglycemia, arginine, vasopressin, exercise and surgery are
blocked by phentolamine (20,45).

Sleep related GH release is

not effected by a or 8 adrenergic blockade.

The site of action

of neurotransmitter is thought to be the hypothalamus since
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neuroantagonists have no effect on GH secretion induced by
direct electrical stimulation of the hypothalamus but do block
GH secretion after amygdaloid and hippocampal stimulation (45).
The release of these hypothalamic factors is mediated via input
from other areas of the brain.

In the rat, electrical stimulation

of the ventromedial nucleus, preoptic area and corticomedial
amygdala inhibit GH secretion, whereas stimulation of the hippocampus,
basolateral amygdala, interpeduncular nucleus and locus coerulus
augment GH secretion (48-49).

Different areas of the brain might

be involved in control of GH at rest than during stress since septal
lesions do not effect basal or physiologic GH fluctuations but
do potentiate the GH response to stress (50).

ACROMEGALY

The effects of chronic elevations of GH on carbohydrate and lipid
metabolism are exemplified by the derangements seen in acromc0^l^ .
Clinically,

the most obvious finding is the increased incidence of

diabetes mellitus, which occurs in 20 to 25 percent of patients (51-52).
The diabetes occurring in patients with acromegaly is characterized
by relative insulin resistance and elevated fasting insulin levels
(53-54).

Additionally,

the initial burst of insulin secretion

seen after a glucose load in normal subjects and in non-diabetic
acromegalics, is decreased in diabetic acromegalics although
total glucose-stimulated insulin secretion may be normal (54).
It has been suggested that the development of diabetes in acromegaly
is a consequence of the failure of insulin secretion to keep pace
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with the demands of insulin resistance

(53,55).

This hypothesis

is supported by studies following acromegalic patients over time.
In these studies,

it was shown that individual patients with normal

glucose tolerance demonstrated marked hyperinsulinemia, whereas
diabetes developed when they became unable to increase their insulin
output in response to glucose

(55).

Even in those acromegalic patients without diabetes
as fasting hyperglycemia and/or glycosuria),
of decreased glucose tolerance.

(defined

there is evidence

In several studies,

intravenous

glucose tolerance tests were performed on non-insulin dependent
patients with normal fasting blood sugars.

Their rate constant for

disappearance of glucose from the blood

was compared with

that of normal subjects.
patients

(53%)

Ikkos el al.

(K)
(56)

found that 9 of 17

had a K<1, whereas all eleven controls had a K>1.

Cerasi and Luft

(57)

found that 2 of 9 patients

(22%)

had a K<1 and

chat the average K in acromegalics and controls were 1.3 and 1.75,
respectively.

Sonksen et al.

5 of 15 patients

(55). similarly found a K<1 in

(33%) with an average K of 1.4 in the acromegalics

and 2.6 in controls.

Results of oral glucose tolerance tests are

in agreement with the results of intravenous testing.
using the criteria of Fajans and Conn
at 2 hours),

Beck et al.

(58),

(glucose greater than 120 mg/dl

found abnormal glucose tolerance in 8 of 12 acromegalics

(67%), while Fineberg et al.

(59)

found an average 2 hour glucose

of 153 mg/dl in the 9 acromegalics studied and 102 mg/dl in controls.
Since none of these studies compared patients with age-matched

controls,

they may be overestimating the frequency of abnormal

glucose tolerance.

However,

it is still evident that a sig¬

nificant proportion of acromegalic patients with fasting euglycemia
are less efficient in disposing of a glucose load than normal
subjects.
Although decreased glucose tolerance is frequently present
in acromegaly,

insulin levels are often elevated.

patients with normal fasting blood sugar,
elevated fasting plasma insulin levels

Among

40 to 80 per cent have

(55,57,59,61).

Glucose-

stimulated insulin secretion is increased approximately three¬
fold in 60 to 70% of patients including both those with normal
and abnormal glucose tolerance

(53,55,58,59,62).

Insulin se¬

cretion in response to non-hyperglycemic stimuli such as arginine
infusion or a protein meal is also elevated in acromegaly

(59).

The presence of hyperinsulinemia without hypoglycemia or
increased glucose tolerance suggests that chronic overproduction
of GH might lead to a state of insulin resistance.

This V pcthosis

is supported by studies in which insulin was infused into the
brachial artery of patients with acromegaly and the arterio¬
venous difference in glucose concentration monitored.
studies,

In these

insulin-induced increases in glucose uptake by muscle

and adipose tissue were decreased between 33 and 50 per cent in
acromegalic patients as compared to controls

(63-65).

Changes in the binding of insulin to its receptor on mono¬
cytes are seen in acromegaly

(66).

Monocytes taken from patients

with acromegaly have a decreased concentration of insulin re¬
ceptor per cell accompanied by an increase in affinity of the
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empty receptor.

The net result is normal insulin binding at

basal insulin concentrations but decreased binding at high insulin
concentrations.

The decrease in receptor concentration is pro¬

portional to the increase in basal insulin, while
concentration,

the decrease in

increases in affinity, and magnitude of insulin

resistance are all proportional to the degree of elevation in GH.
It is not yet known wfiether the insulin resistance seen in
acromegaly is due to direct stimulation by GH of insulin se¬
cretion leading to insulin-induced binding changes,

by GH-induced

inhibition of glucose utilization at a site distal to the re¬
ceptor leading to secondary hyperinsulinemia and resultant changes
in binding,

or to a direct effect of GH on the insulin receptor.

Elevations in free fatty acids
seen in acromegaly

(55,57,58,62),

(FFA)

are not commonly

and glucose administration is

as effective in suppressing FFA levels in acromegalic patients
t.j Jn

itrols

(55,57).

However,

studies of forearm FFA metabo¬

lism show an increase in output of FFA in the basal state in patients

With acromegaly (64-65).

Interestingly,insulin is as effective

in suppressing FFA output in acromegalic patients as it is in
controls, although it is less effective in increasing glucose
uptake,

This suggests that FFA levels are normal in acromegaly

because elevated plasma insulin levels compensate for the effects

pf GH on FFA release.
lipid Metabolism
Rats
GH has been shown to exert both insulin-like and anti-

insulin effects on lipid metabolism when administered
In the rat,

acutely.

this has been studied mainly in hypophysectomized

or pancreactomized animals using supraphysiologic doses of GH.
The insulin-like action consists of an early decrease in FFA
/

levels.

This can be demonstrated both in vivo and in vitro.

In

vitro studies of rat adipose tissue show inhibition of basal
lipolysis and suppression of epinephrine- induced lipolysis
(67-68).

In vivo,

a fall in serum FFA levels is seen 30 to 60

minutes after injection of GH

(69-71).

If studies last longer than one hour,
effect ot GH is uncovered.

By one hour after GH injection,

levels begin to rise and continue to
hours

(70).

a pronounced lipolytic
FFA

increase for at least 5

Three and one-half hours after injection of 50 yg GH,

fatty acid synthesis from glucose increases, while fatty acid uptake
by adipose tissues decreases
physectomized rats,

(69).

In pancreactomized hypo¬

ketones and FFA levels both rise

(72).

In

vitro assays have found increased lipolysis by two hours after
administration of GH

(73).

Dexamethasone potentiates the lipo¬

lytic effects of GH both in vivo and in vitro

(72-74).

These

late lipolytic effects can be abolished by administration of in¬
hibitors of protein synthesis
synthesis

(e.g.

exposure to GH

(e.g.

cycloheximide)

and RNA

Actinomycin D) within the first two hours after
(69,73,75).

These inhibitors also prolong the

early anti-lipolytic effects of GH

(76).

Studies examining the effects of GH on hepatic lipid
metabolism have yielded conflicting results.

Lotspeich &

Peterson

(77)

injected rats with 1 mg of GH per day for four days

then gave 5 mg of GH/100 gm body weight on the fifth day and
sacrificed the rats 2 hours later.

Isolated liver slices

showed greatly increased synthesis of acetoacetate and increased
liver fat.

Penhos et al.

(78)

perfused rat livers with 0.5 mg/ml

of GH for 90 minutes and found increased hepatic uptake of trigly
cerides and FFA but no increase in ketone production.
et al.

(72)

Chernick

perfused rat livers with 5 yg/ml GH for 90 minutes

and saw no increase in hepatic uptake of FFA. cr ketone production
The differences between these studies probably

reflect the

variations in dose of GH and duration of exposure.

The study

using the most physiologic dose showed no effect of GH on
either hepatic uptake of FFA or hepatic ketone production

(72).

Dogs
Data in dogs are also consistent with an early hypolipodemic action of GH,

As was

used pharmacologic quantities of gH.

ca:° in rats,

these studies

An early decline in FFA

levels after injection with GH is followed by a 4-fold rise in
FFA and glycerol levels within three hours as well as an increase
In the turnover of FFA and in the percentage of total respiratory
CO^ derived from FFA (79).

Of interest

the observation that

the rise in FFA levels only lasts for five to ten days.
that,

After

FFA levels return to baseline despite the continued ad¬

ministration of GH

(80-82),

The return to baseline is not due

to depletion of fat stores since norepinephrine stimulated lipolysis can still occur

(79).

It is also not due to increases in
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plasma insulin since insulin levels increase several days be¬
fore the decline in FFA levels is seen

(79).

Humans
In adult humans,
duced in animals.

GH exerts effects similar to those in¬

There have been several reports of

an early decrease in FFA levels following administration of
large doses of GH.

For example,

4 mg GH intravenously causes

a 21 per cent fall in plasma FFAs at one hour

(83), while 10 mg

GH intravenously causes a 33 percent decline in plasma FFA
levels by

n minutes due to a decrease in output

(84).

Increases in plasma FFA levels are seen- 2 to 4 hours after
injection of GH.

Several groups have found approximately a 100

percent increase in FFA levels after injection of 4 to 8 mg of
GH (80,84-87).

GH-induced increases in FFA levels are inhibited

by the administration of

glucose

<=i* h as nicotinamide
acid

(86).

(87)

(80)

and by inhibitors of lipo-

and 5-methylpyrazole-3-carboxylic

Insulin is as effective in suppressing lipolysis

in subjects injected with GH 4 hours before insulin injection or
in subjects infused simultaneously with insulin and GH as it is
in control subjects

(64,84).

The effect of GH on peripheral uptake and output of FFA
has been examined in studies where GH was infused into the
brachial artery of normal volunteers.

Changes in the arterial

minus deep venous FFA concentrations were taken as representative
of muscle metabolism and changes in arterial minus superficial
venous FFA concentrations were taken as representative of adipose
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tissue metabolism.

ng/ml were

achieved,

by muscle was

output

When

When arterial GH concentrations

seen

an

200 ng/ml)

tissue beginning at

concentration of

however,

study

be due

(83).

only

in

1 mg of

of

in

the

dose

All

examined

at

3

so

that

at

to ascribe

this

least

effect

baseline well before

the

group

insulin

that had

levels.

tissue

that

exposure

3

In

this

groups.

One

The second

of

the

experiment,

group was

study.

in

the

infused

order

group

to

of GH

lipolytic effect.

groups but

given

A third

the ketogenic effects

three

GH.

studied

group was

received heparin

its

to

Similar

group

treated

earlier had significantly greater increases

The authors

delayed

(89).

the start

independently of

12 hours

duration of

study.

groups

ketone bodies.

is

to

adipose

in humans has been

into

the

1 hour

controls.

1 mg GH

or

diabetics

FFA levels were achieved in all

with

GH on muscle or

GH on ketogenesis

plasma FFA levels

could be

(28.4 ng/ml

studies may

GH 12 hours before

elevate

(64,88).

The discrepancy between these

subjects were divided

as

forty minutes

duration of

with 4 yg/kg GH for

served

in FFA

90 minute

insulin dependent

diabetic

of

300

in FFA uptake

increase

infused

seen during the

to differences

The effect

GH were

no effect

lipid metabolism was

the

increase

followed by a sustained

from adipose

lower

immediate

of

to

concluded

60 minutes

that

GH exerts ketogenic activity

in onset.

GH, since GH

However,

levels had

the heparin injection was

increased ketogenesis had

Unless

GH itself

caused

in

it

returned

given.

difficult

to

Also,

significantly

the decreased

is

lower

insulin

levels,

it

is

unlikely

that

GH was

responsible

for

the

increased

ketogenesis.

Another

study examined

insulin-dependent

statin was

given

the

diabetics

to

role

(90).

suppress

of basal GH levels

In

this

glucagon and

GH and insulin were infused along with

effects were

seen.

However,

plasma concentration of

levels

of FFA,

glycerol and

by 1 hour and were

hours.

lipolysis

No

increment

stress,

concluded

in GH,

examined

such as

infused

to

those

levels

to

increase

at

4

to

6

of GH can augment

in the absence of

insulin.

of physiologic

seen during various

on lipid metabolism in normal

a

insulin,

than controls

that basal

the effects

When

achieve

8-hydroxybutyrate began

and ketogenesis only

study has

secretion.

in the absence of

significantly higher

The authors

GH

somato¬

the somatostatin,no

when GH was

6 ng/ml

study,

in

types

of

subjects.

Carbohydrate Metabolism

Rats

The dichotomy between

on

lipid metabolism are

metabolism.

of

GH leads

(71,77,91).

also apparent

In the normal

to

a reduction

In vitro

the early and

in blood

incubation of

in an

oxidation within 20

60 minutes

effects

can be

concentrations

an increase

duplicated by

of

glucose

in regard

to

sugar within

in

20 minutes

glucose uptake

(68,91-93).

incubation of

suggesting that

of

injection

rat muscle,adipose or kidney

increase

in cellular uptake

of GH

glucose

and hypophysectomized rat,

tissue with GH results

to

late effects

glucose

These

and

early

tissue with high

they might be

(93).

due

Increased

to

cellular uptake of glucose could be mediated by changes in
insulin secretion or degradation or in the tissue response to
insulin.

The importance of insulin in the acute hypoglycemic

action of GH is supported by the observation that no acute hypo¬
glycemic effect is seen after GH injection into insulin-deplete
diabetic rats

(94).

Although plasma insulin levels are not

elevated within the first hour after exposure to GH,

insulin

degradation has been reported to transiently decrease

(91)

and insulin release from the pancreas of hypophysectomized
rats

(93;

and normal rats

(96)

has been reported to

increase.

Exposure to GH for longer than 1 to 2 hours causes hyper¬
glycemia and decreased glucose utilization in the rat.
hours after exposure to GH,

Three

it is possible to show decreased glucose

utilization in adipose tissue

(69).

Four days of treatment with

GH and dexamethasone result in glycosuria in partially pancreatomized rats

(98).

Twelve days of GH injection cause in¬

creases in blood glucose and decreased glucose uptake in
vitro in hypophysectomized rats

(99).

These later hyperglycemic

effects can be prevented by exposure to inhibitors of protein and
RNA synthesis.
of GH

These also prolong the early hypoglycemic actions

(93).
Prolonged exposure to GH in rats has been reported to cause

hyperinsulinemia and insulin resistance

(100).

Rats implanted

with a GH-secreting tumor have a 5-fold increase in fasting
insulin levels,

increased pancreatic islet volume and insulin

content and increased glucose stimulated insulin secretion in

vitro.

This is accompanied by decreased utilization of glu¬

cose by diaphragm and adipose tissue in vitro

(100).

Conversely,

islets taken from hypophysectomized rats have a decreased
insulin content and release which returns towards normal after
3 days of treatment with GH

(101).

Injection of 1 mg GH twice

a day for 5 days into normal rats results in a 2 fold increase
in plasma insulin levels and a 10 mg/dl increase in blood sugar
(102).

This is accompanied by a decrease in the concentration

of insulin receptors on hepatic membranes a^d an increase in the
affinity of the empty receptor

(102),

changes similar to these

seen in monocytes of patients with acromegaly

(66).

Dogs
In the dog GH causes transient hypoglycemia in hypo¬
physectomized animals but not in normal dogs.
by an increase in glucose uptake

(79).

Tnis is accompanied

Whether insulin is necessary

for the hypoglycemic effect in dogs is not clear,since,in acutely
pancreactomized dogs,GH also causes

transient hypoglycemia

This is the opposite of the situation in the rat.

(103).

The differences

may be due to the presence of residual insulin in the acutely
pancreactomized dogs.
More prolonged exposure to GH in both normal and hypo¬
physectomized dogs causes increases in blood glucose and insulin
(79,

82,104-105).

The hyperglycemic reaction is dependent upon

the nutritional status of the dog.

Dogs that have been fasted

for four to five days before receiving GH maintain a normal
blood glucose,but this is in the presence of marked hyperinsulinemia and insulin resistance

(79).

The hyperglycemia is

due to a decrease in peripheral glucose clearance and an
increase in the hepatic release of glucose (79,82,105).
Humans
In normal humans, pharmacologic doses of GH have been
shown to induce a transient decrease in blood glucose of
approximately 10 mg/dl within the first hour after exposure
to GH (83-84,

106-107).

This has been attributed to a de¬

crease in glucose output (84,107).

Very early after GH

administration (10 minutes), it can be shown that glucose
utilization as measured by the intravenous glucose tolerance
test (IVGTT) increases by 30 percent (62,85).
Longer term administration of pharmacologic doses of GH
causes increases in blood glucose only in hypopituitary patients
(53) and obese patients during a period of starvation (108).
However,

results of IVGTT in normal subjects reveal a 50 per

cent decline in glucose utilization 2 to 5 hours after GH
injection (62,85-87).

Glucose-stimulated insulin release has

been reported to increase (62,106),

to remain unchanged (87),

and to decrease (109) following GH administration.
To evaluate the effect of acute administration of GH

on

peripheral glucose metabolism, GH was infused into the brachial
artery of normal subjects while arteriovenous
glucose concentration were measured.

differences in

When pharmacologic doses

of GH were infused, an immediate 50 percent reduction in glucose
uptake by muscle and adipose tissue was seen (64,88).

When more

physiologic doses were infused for 30 minutes, a 30 percent decrease

in glucose uptake into muscle
neither study was

tissue was seen (83).

In

any early insulin-like action observed.

There is some evidence that short term GH infusions can
lead to a state of insulin resistance.

Infusion of GH into

the brachial artery along with insulin blocks
insulin on glucose uptake

(64,

65).

the effects of

Giving an insulin infusion

four hours after 5 mg of GH results in attenuation of insulin
induced increases in glucose uptake

(84).

Amino acid-stimu¬

lated insulin release is 2-fold greater in GH treated sub¬
jects than in controls but does not cause any change in
blood sugar

(110).

Finally,

obese subjects in the fed state

given GH have increased insulin levels but normal blood sugars
(108).
Most of the previously cited studies were done using
pharmacologic doses of GH.

An attempt to examine the consequences

of physiologic fluctuations in GH levels was made by Yalow et al.
till).

They provoked increases in plasma GH by giving a 100

gram oral glucose load to normal subjects.
rise,

Plasma GH began to

in response to falling blood glucose levels,

after the oral

3 to 4 hours

glucose load was given and peaked at about 13 ng/ml

at 4 to 5 hours.Six hours after the original glucose load,
100 gm oral GTT was performed.

a repeat

In those subjects who had shown

an elevation in GH in response to the first glucose load,

the

second GTT showed significantly decreased glucose tolerance and
markedly increased glucose-stimulated insulin release.

Those

subjects who did not augment their GH secretion in response to
the original glucose load had no deterioration of glucose

tolerance during the second test.

This seems to indicate

that physiologic elevations in plasma GH levels cause a deterior¬
ation in glucose tolerance and increased insulin secretion.

However,

when the oral GTT was repeated 4 hours after the initial glucose
load,

at the time of the peak GH response,

glucose tolerance

was only slightly impaired and glucose-stimulated insulin
secretion was not increased.

Finally,

repeating the oral GTT 3

hours after the initial glucose load resulted in improved glucose
tolerance and decreased insulin secretin
in interpreting this set of experiments

The major difficulty
cnar many factors

other than GH are responsive to changes in glucose levels.

It is

likely that fluctuations in the plasma levels of epinephrine,
norepinephrine,

cortisol and glucagon occurred CH2)

and also

influenced the results.
In another series of studies,

GH was infused into healthy

subjects for 30 minutes at diffciart dc es
two lowest doses,

5 and 10 yg/kg,

The

resulted in post-infusion GH

concentrations of 20 and 48 ng/ml,
seen during stress.

(109,113-114),

leyels simulating those

Blood glucose was found to decrease slightly

but significantly only in the group receiving a yg/kg GH infusions,
not in the group that received 10 yg/kg CII infusions.

However,

both groups showed significant decreases in basal plasma insulin
that were apparent by 15 minutes after the start of the GH in¬
fusion and lasted up to 60 minutes after the infusion ended

(109).

There was no correlation between the timing and the magnitude of
the changes in insulin and glucose.

When glucose utilization was

estimated by the IVGTT,

it was found that glucose

tolerance

measured at the end of a 30 minute 10 yg/kg GH infusion had
deteriorated significantly

(113).

However,

glucose tolerance

continued to deteriorate even further over the five hours
following the end of the infusion despite

the fact that GH

levels had returned to baseline by 1 hour after the end of
GH infusion

(109,113).

the

Glucose-stimulated insulin secretion

was unaffected by infusion of physiologic doses of GH in this
study

(113), but in a later study which divided the subjects into

3 groups, mild diabetics,

low and high insulin responders,

glucose-stimulated insulin secretion was found to decrease in the
diabetic and low insulin responders
however,

(114).

decreased in all three groups.

difficulties

Glucose tolerance,

There are several

in interpreting these studies.

One problem is that

GH concentrations were not kept constant during the study period
making it unclear whether decreased glucose tolerance and suppress
of insulin release were in fact due to the GH administered
earlier.

5 hour

Another difficulty is explaining the suppression of

insulin levels since most of the data available in
animals support the hypothesis
of insulin.

humans and

that GH leads to increased levels

There is no information available on the effects

of a sustained increase of GH to levels seen normally during
stress on insulin secretion,

glucose levels,

and glucose tolerance

Protein Metabolism
Animals
It has been known that GH influences protein metabolism
since the early studies of Evans and Long
and Cushing

(116)

(115)

and Teal

demonstrated increased growth of normal rats

and dogs treated with pituitary extracts.
discovered that

Later it was

treatment of normal or hypophysectomized

animat with pharmacological doses of GH caused

a decrease

in both blood amino nitrogen levels and urinary nitrogen
excretion that is apparent by one hour after exposure to
GH (117,

118)

and lasts during several weeks of GH therapy.

The effects of GH on protein metabolism have recently been
reviewed

(119).

One action of GH is

to increase the rate of uptake of

amino acids into skeletal muscle,

cardiac muscle and liver.

This occurs after a 30 to 60 minute lag period and disappears
after 3 to 4 hours

(119).

Administration of inhibitors of

protein synthesis such as puromycin and cycloheximide or
inhibitors of RNA synthesis such as Actinomycin D prolong the
stimulatory action of GH on amino acid uptake

(119) .

In vitro

studies using radioactively labelled amino acids have shown
tnut GH increase the uptake of glycine,

alanine,

serine,

threonine,histidine, proline, tryptophan, asparagine and
glutamine but does not effect the rate of uptake of valine,
phenylalanine,

leucine, methionine,

glutamate or aspartic acid

tyrosine,

lysine,

arginine,

(120).

It has been suggested that augmentation of amino acid
transport is mediated by GH-induced increases in plasma insulin
(119).

This is unlikely since insulin levels do not increase

until after the peak increase in amino acid uptake has occurred.
In addition,

increased uptake occurs after exposure to GH in

vitro as well as in vivo (119).

Finally, inhibition of

phosphodiesterase with theophylline or caffiene blocks GH
induced changes in animo acid transport but does not affect in¬
sulin-induced transport changes (119).
GH also acts to increase the rate of protein synthesis
in muscle and liver (119).

This effect occurs after a 30

minute lag period but,unlike the increase in amino acid uptake
persists for at least several days.

In vitro studies using

labelled amino acids have shown a 30 to 50 percent increase in
incorporaf rm of glycine, alanine, serine, proline, histidine,
threonine, methionine, tryptophan,

tyrosine, leucine, valine,

phenylalanine, lysine and arginine into protein (120).

Thus

different amino acids are involved in transport and synthetic
effects of GH.

These two processes were also shown to be

separate in a study in which amino acid uptake was blocked by
removal of Na from the incubation medium (121).

Under these

conditions, stimulation of protein synthesis is unaffected.
GH causes increased .protein synthesis ,at least in part, by
enhancing the catalytic activityof ribosomes (122) and increasing
the number of ribosomes (123).

The changes in ribosomal activity

reach a maximum at 18 to 24 hours after exposure to GH.
Salmon and Duvale (124) suggested that somatomedins,
not GH, are the ultimate stimulus of increased protein
synthesis in muscle.

However ,this was disputed by Kyosto and

Nutting (125) who found that while protein synthesis began to
increase after 30 minutes, somatomedin levels in blood did not
begin to increase for 6 to 24 hours after administration of GH.

This does not exclude the possibility that somatomedins mediate
the prolonged duration of the increase in protein synthesis.
The above studies on amino acid uptake and protein syn¬
thesis have all been performed on hypophysectomized animals.
It has not been possible to demonstrate any changes in uptake
or synthesis in normal adult rats even with administration of
pharmacologic quantities of GH.

Recently, enhancement of

both these processes has been found after in vivo and in vitro
GH treatment in young (17 to 18 day) normal fats (126-128).
The characteristics of enhanced amino ana transport were similar
to those observed in hypophysectomized animals,whereas only

a

transient increase in protein synthesis was found.
Humans
The effects of GH on protein metabolism in human sub¬
jects has not been studied as extensively as in animals.

It

is known that treatment of hypo--' tuifry patients and normal
subject with large doses of GH results in decreased urinary
nitrogen excretion, decreased plasma amino nitrogen and a
positive nitrogen balance (129-131).

Normal subjects are less

sensitive than hypopituitary patients to GH administration (132).
The response of obese subjects treated with large doses of GH
for 5 days is dependent upon their nutritional status (108),
Patients in the fed state respond to GH by decreasing urinary
excretion of urea and ammonia with a resultant positive nitrogen
balance.

After prolonged starvation of obese subjects, GH

causes a 50 percent decrease in urea excretion but this is
balanced by a 50 percent increase in ammonia excretion so
that there is no net change in nitrogen balance.

The authors

concluded from this that GH does act to decrease protein
catabolism,but, in starvation,the lipolytic and ketogenic effects
of GH result in increased urinary acid secretion in the form
of ammonia and oppose the protein-sparing effects of GH.
The effect of GH on specific amino acid levels in
blood has been examined in normal patients after injection of
4 mg GH intravenously (133).

Leucine decreased by 50 percent

30 minutes after GH injection and levels remained depressed for
the 4 hour duration of the study.

Methionine, tyrosine, and

alanine levels fell significantly by 30 mnutes but returned
to baseline by 2 hours.

Decreases in histidine were not seen

until 2 hours after GH exposure.

Glycine levels actually

rose at 30 and 60 minutes and then returned to baseline.
other amino acids were studied.

No

The acute effects of physiologi

increments in GH on amino acid levels in normal subjects are
not known.

MATERIALS AND METHODS
Subj ects
Studies were performed on 8 healthy subjects, 5 male and 3
female, with a mean age of 26.4 ± 4.2 years.

All were within

15 percent of ideal body weight (Metropolitan Life Insurance
Tables, 1959).

Details are in Table 1.

Subjects consumed weight-

maintaining diets containing at least 200 gm of carbohydrate and
were taking no drugs.

All had negative primary family histories

for diabetes and none had an elevated fasting plasma glucose.
The subjects were informed of the nature, purpose and possible risks
of the study before their written, voluntary consent to
participate was obtained.

Prior approval for these investigations

was obtained from the Yale Human Investigations Committee.
Experimental Design
Studies were begun in the morning after a 12 to 15 hour
overnight fast.

A polyethylene catheter was inserted into en

antecubital vein for blood sampling and in the contralateral vein
for administration of human growth hormone (HGH).
protocols were employed in each subject.

Two experimental

In the'■first, HGH, at

a dose of 3 yg/kg/hr, was infused for 8 hours at a flow rate of
14.4 ml/hr by a Yale Digital Infusion Pump.

HGH (obtained from the

National Pituitary Agency) was prepared by first dissolving it in
10 ml of distilled water and then diluting it into a larger volume
of 0.9% NaCl.

In the second study, physiologic saline, rather than

HGH, was infused for 8 hours under identical conditions.

After

either HGH or saline had been infused for 5 hours, a 3 hour 100 gm

29

oral glucose tolerance was begun (Dexerol).
studies were performed in random order.

The first four sets of

In the second four sets of

experiments, the saline infusions were performed first because of
concern about possible long term effects of HGH infusion.
Some subjects also participated in a third study in which
0.9% NaCl or 3 yg/kg/hr HGH were infused for 5 hours for measurement
of insulin binding to monocytes and erythrocytes.

Individual studies

were separated by a minimum of 48 hours and a maximum of 14 days.
No subject experienced any unpleasant side effects.
SAMPLING PROCEDURES
Blood fcr glucose measurement was drawn at times t=-15,0,30,60,120,
180 and 240 minutes and at 15-30 minute intervals thereafter.

Samples

were immediately centrifuged and the plasma used for assay of glucose.
Samples for plasma immunoreactive insulin were collected in heparin¬
ized tubes at the same time intervals as the glucose samples were
collected.
3ml of blood was added to tubes containing 0.3ml Trasylol and
10.5 mg EDTA for determination of immunoreactive glucagon.

Samples were

obtained at t=-15,0 and 60 minutes and every 60 minutes thereafter up
to 480 minutes.
Samples for measurement of FFA were collected in heparinized tubes
at t=-15,0 and 60 minutes and every 60 minutes thereafter up to 300 minutes.
Equal volumes of blood were mixed with 6.0% perchloric acid for
determination of acetoacetate and

g-hydroxybutyrate.

Samples were

obtained at t=-15,0 and 60 minutes and every 60 minutes thereafter up
to 300 minutes.
Samples for measurement of plasma amino acids were obtained in
heparinized tubes at the same time intervals as the ketone samples were
obtained.

The plasma was deproteinized with 10% sulfasalicylic acid.

Plasma for measurement of HGH was obtained at t=-15,0,60,180
and 300 minutes and at 30 to 60 minute intervals thereafter.
At t=0 and 240 minutes blood was collected in heparinized
tubes for measurement of insulin binding to monocytes and ery¬
throcytes .
Glucose and insulin binding assays were performed on the
day of the study.

All other samples were stored at -20°C until

used for analyses.
CHEMICAL ANALYSES
Plasma glucose was assayed by the glucose oxidase method
(134) on a Beckman Glucose Analyzer (Beckman Instruments,
Fullerton, California).
Plasma immunoreactive insulin was determined by radioimmuno¬
assay using talc to separate bound from free insulin (135).
Plasma immunoreactive glucagon was measured by radioimmuno¬
assay using the Unger 30K antibody (136).
Plasma growth hormone was measured by radioimmunoassay (137)
by the Yale New Haven Hospital Clinical Immunology Laboratory.
8-hydroxybutyrate and acetoacetate concentrations in blood
were determined by the method of Williamson, Mellanby, and Krebs
(138).
FFA levels were determined enzymatically by a modification of
the method of Dole (139).
Plasma amino acids were assayed by automatic ion-exchange
chromatography (140).

This method measures neutral and acidic

but not basic amino acids.

Insulin binding to monocytes was determined using ^^1monoiodoinsulin (141).

Monocytes were isolated from 50 ml of

whole blood and incubated for 3 hours with 0.2 ng/ml ^^i-insulin
in the presence and absence of unlabelled porcine insulin.
specific binding of

125

The

I-insulin was calculated by subtracting

nonspecific binding (^2“*I-insulin bound in the presence of un¬
labelled insulin) from total 125I-insulin binding (125I-insulin
bound in the absence of unlabelled insulin),

Total binding

capacity was calculated by Scatchard analysis (142).
Insulin binding to erythrocytes was determined by the method
of Gambhir, Archer, and Carter (143).

Erythrocytes were isolated

from 10 ml of blood using a Ficoll-Hypaque gradient and incubated
IOC

for 2.5 hours with x xI-insulin in the presence and absence of
unlabelled insulin.

RBC-bound insulin was separated from free

insulin using dibutyl phthalare.

Specific binding and total

receptor capcity were calculated as in the monocyte binding studies.
STATISTICAL METHODS
All values represent the mean of duplicate determinations of
each sample.

Data is given as the mean - standard error.

was performed using the Students T-test.

Analyses

The paired t-test was

used to compare results from GH infusion with results from the
control saline infusion (144).
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TABLE I

Subject

Age

Sex

Height
(cm)

Weight

Percent Normal Weight

(kg)

V.P.

18

M

180

61.4

85

N.R.

38

F

157

53.6

110

D.F.

35

M

183

79.5

107

L. S.

22

F

170

62.3

107

T.B.

18

i'i

175

65.9

96

T.W.

34

M

175

72.7

106

C.C.

23

F

180

72.7

108

B. 0.

23

M

188

85.0

107
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RESULTS

Growth Hormone Levels
Mean preinfusion GH levels were similar in both the saline and
GH infusion studies (saline, 2.2±0.8 ng/ml vs GH, 1.8±0.3 ng/ml, p>0.05).
As can be seen in Figure 1, GH levels increased rapidly during the
infusion of GH, reaching a stable plateau within 2 hours.
mean plateau value was 35.2±4.4 ng/ml.

The

Individual preinfusion and

plateau GH concentrations are shown in Table 2.
Effect of GH on Basal Substrates
The first 5 hours of these studies. t'ofnre the start of the oral
glucose tolerance test,

is considered the basal period.

Mean

basal glucose concentrations during GH and saline infusion are given
in Table 3.

Glucose levels remained nearly constant throughout

the basal period and there was no significant difference between the
GH and corresponding saline control glucose levels.
Figure 2 demonstrates the -linages in FFA and ketone levels that
occurred during the infusion of GH.

FFA levels (491±43yM before GH

infusion) increased by 76% in the GH group (to 866±74yM) whereas
they increased by only 25% (to 576±66yM) in th^ fasting saline
control group.

The differences between the corresponding saline

and GH FFA levels were statistically significant after 180 minutes
(p<0.05-0.005).

Similiarly, blood ketone levels (0.110±0.08mM before

GH infusion)- increased 86% during the GH infusions and were significanly higher than the corresponding saline control values at 180
minutes (p<0.05) and 300 minutes (p<0.01).
In 3 subjects, 11 different amino acids were measured during the

infusion of GH

(Table 4).

Since in these studies only plasma

alanine appeared to change substantially, we elected to further
evaluate this question in all subjects by measuring alanine using
a short column technique.
on glycine, valine,
Table 5.

The latter studies also provided data

leucine,

and isoleucine which is included in

These data show that alanine decreased by 22% during the

GH infusion and was significantly lower than preinfusion values at
240 minutes

Cp<0.001)

and 300 minutes

(p<0.005).

there was a small decline in plasma glycine

(8%,

In addition,
p<0.05),

whereas

the concentrations of the branch chained amino acids(valine,
and isoleucine)

remained unchanged.

leucine,

There were no significant

changes in amino acid concentrations during the control saline
infusions.
Effect of GH on Basal Hormone Levels
As shown in Table 3,

plasma insulin levels were 35% greater in

the GH-infused subjects than in the saline controls at 5 hours.
Figure 3 demonstrates 0 and 5 hour plasma insulin levels in
saline and GH groups.

It is apparent that

insulin levels

the

tended to

increase during the GH infusions whereas they tended to decrease
during the saline infusions.

The difference between the two groups

became significant by 5 hours

(GH,

yU/ml,

p<0.005).

In contrast,

16.3±l.lyU/ml vs saline,

12.1t0.9

basal plasma glucagon levels de¬

creased slightly in control and GH studies and never differed
significantly between groups

(Table 3).

Effect of GH on the Response to a Glucose Load
The GH response to a 100 gram oral glucose load is shown in
Figure 1.

As expected

(5,13), mean GH levels

tended to fall in the

35

saline control subjects from 4.5±1.7 ng/ml at 300 minutes to 1.87
±0.5 ng/ml by 60 minutes after ingestion of glucose.
changes were not statistically significant.

However,

these

After 60 minutes, GH

levels returned to values seen prior to glucose.

In the GH-infused

subjects, plasma GH remained unchanged.
Figure 4 demonstrates the mean glucose and insulin responses to
the 100 gram oral glucose load.

GH treatment resulted in marked

deterioration in glucose tolerance with plasma glucose levels 30 to
50 mg/dl above the corresponding saline '•'or.tiiol values from 90
minutes after glucose administration until i

tne end of the study

(90 min., 170+11 mg/dl vs 127±11 mg/dl, p<.0.005; 120 min., 162±12 mg/dl
vs 121±7 mg/dl, p<0.01; 180 min., 124±13 mg/dl vs 85±6 mg/dl, p<0.05).
The incremental area under the glucose curve during the glucose
tolerance test was increased by 85% in the GH-treated subjects as
compared to the saline controls (11078±1571 mg/dl/180 min. vs 5885
±1069 mg/dl/180 min., p<0.005).
The decreased glucose tolerance occurred despite an increase in
insulin secretion.

Mean peak insulin levels were 2-fold higher in

GH-treated subjects

(168±34 yU/ml vs 86±18 yU/ml, p<0.005) and the

incremental area under the insulin curve was 82% greater than in
the saline control (18404±3306 yU/ml/i8C min. vs 10145±2272 yU/ml/180
min., p<0.005).

Insulin levels in the GH-infused subjects were

significantly higher than in the saline controls at 60 minutes
(103±19 yU/ml vs 86±18 yU/ml, p<0.005), 120 minutes (168±34 yU/ml vs
80±22 yU/ml, p<0,005), and 180 minutes (128±28 yU/ml vs 41±7 yU/ml, p<0.02)
after glucose ingestion.

The time course of the insulin response also

differed between groups.

During the saline infusions, peak insulin
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levels occurred at 60 minutes whereas during the GH infusions,
insulin levels did not peak until 120 minutes after glucose
administration.
Figure 5 compares individual 120 minute glucose and insulin
levels in the GH and saline groups.
(open circles)

It shows that 2

of 8 subjects .

did not have significantly different glucose levels

in the GH and saline infusions but that all subjects had elevated
insulin responses after GH infusion.
responses of the 2

The glucose and insulin

subjects whose glucose tolerance did not de¬

teriorate after GH treatment are descru'K ’
Although the total area under their glucose

more detail in Figure 6.
curves remained unchanged,

the area under their insulin curves increased by 67%
and 73%

(subject D.F.)

(subject L.S.).

During the glucose tolerance test,

plasma glucagon decreased by

30% in the GH-treated subjects and by 12% in the saline controls
(Table 6) .

The differences between th<_ two groups never attained

statistical significance.
There was no correlation between the absolute decrease in
glucose tolerance and the absolute increase ir. the insulin response
(R=-0.2,
insulin

p>0.05)
(R= 0.3,

magnitude of
or insulin

or between the percentage changes in glucose and
p>0.05).

Nor was the?:° any relationship between the

the plateau GH elevation and the glucose

(R=0.2,

p>0.05)

(R=-0.07,

response to the glucose load.

p>0.05)
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TABLE 2

Individual Growth Hormone Levels

0
Minutes

Plateau

HGH

V.P.

2

44

ng/ml

N.R.

1

28

D.F.

1

40

L.S.

3

25

T.B.

1

25

T.W.

2

35

C.C.

2

25

B.O.

1

60

Mean

-L

SEM

1

f,

* v-/

0.25

4

FIGURE 1

EFFECT OF GROWTH
ON PLASMA GROWTH

HORMONE
HORMONE

INFUSION
LEVELS

100 gm oral glucose

i
PLASMA
HGH
(ng /ml)
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DISCUSSION
The current data demonstrate that acute physiologic
elevations of plasma GH levels, which do not affect basal
plasma glucose concentrations, result in marked deterioration
of glucose tolerance.

In addition, GH infusion causes elevations

in basal FFA and ketone levels, in the face of a rise in plasma
insulin concentration, as well as a reduction of plasma alanine
levels.

The magnitude of the elevations in GH achieved during the

GH infusions were in the range of those commonly seen during
surgery (5,18-22), infection (25-28), exercise (5,15,17),
diabetic ketoacidosis (7,29-33), uremia (37-39) and cirrhosis
(34-46).

Although in some situations only transient GH elevations

are observed (17,19),

in others, such as severe trauma (145),

major surgery (18,22) and diabetic ketoacidosis (29,32), GH
often remains elevated for more prolonged periods of time, ranging
from 5 to 6 hours (29)

to several days (18,22,145).

Thus, it is

likely that our findings are relevant to the metabolic
seen during severe stress.
After an overnight fast, plasma glucose concentrations are
Maintained at a constant level by release of glucose from the liver
at a rate equal to the rate of glucose utilization by peripheral
tissue (146).

Approximately 70% to 75% of hepatic glucose release

is derived from gluconeogenesis (146).

In this study, plasma

glucose concentrations did not differ significantly in the GHtreated subjects as compared to the saline controls.

In contrast,

several groups have reported a slight decrease in plasma glucose
levels 30 to 60 minutes after administration of pharmacologic
quantities of GH (83-84, 106-107).

The present data support the

view that acute hypoglycemia is a pharmacologic, not a physiologic,
action of GH and that physiologic elevations of GH do not have a
major effect on basal hepatic glucose output or on basal peripheral
glucose utilization.
Despite the maintenance of normal basal glucose levels
during the infusion of GH,
reduced.

glucose tolerance was significantly

This is similar to the findings in studies using

pharmacologic quantities of GH (62,85-87) and to the findings
in acromegaly (55-59) of deterioration in glucose tolerance in
many, but not all,subjects.

It is of interest in the regard,

that in two of our patients,GH had little effect on glucose
tolerance, although insulin secretion was enhanced in these
individuals.
In normal postabsorptive subjects, a 100 gram oral glucose
load is distributed throughout the body as follows: 1)

Less

_L n 57 remains in the glucose space after 3 hours, 2) 25% is
utilized by noninsulin-dependent tissue, such as brain and renal
medulla, to meet ongoing metabolic needs,

3)

15% is utilized by

insulin-dependent peripheral adipose and muscle cells, and 4)
55% to 60% is taken up by the liver (146).

In addition, hepatic

glucose production decreases to 75% to 80% below basal levels (147).
GH could conceivably effect any one of the above steps,
although there is no evidence to suggest that it alters the space
of glucose distribution or that it effects the utilization of
glucose by insulin-independent, glucose-dependent tissue like
the brain.

Adamson et al.(107) observed that pharmacologic doses

of GH actually inhibited splanchnic glucose production by 30% to

40% in fasting subjects and had no effect on the hepatic response
to an intravenous glucose load.

These findings suggest that the

effect of GH to decrease glucose tolerance may not be mediated
by an effect on hepatic glucose output.

Since the hepatic

response to oral and intravenous glucose differ, with significantly
less splanchnic glucose uptake after an intravenous glucose load
as compared to an oral glucose load (148), these findings do not
eliminate the possibility that GH had an effect on hepatic glucose
uptake.

Finally, evidence from other studies suggests that GH

causes decreased peripheral uptake of glucose by muscle and fat
tissue (64,

83, 88).

Since peripheral uptake by adipose and muscle

cells accounts for the disposal of 15% of an oral glucose load, it
might explain the decreased glucose tolerance observed in this study
While earlier studies have reported increases in circulating
FFA 2 to 4 hours after administration of pharmacologic doses of
GH (80, 84-87), the effect of physiologic GH elevations have not
previously been examined.

Our findings indicate that the pattern

of response is quite similar whether physiologic or pharmacologic
doses are given, i.e. FFA begin to increase 2 hours after administra
tion of GH to approximately 100% preinfusion values.

In our

studies, there was no evidence of an early hypolipademic effect,
which supports the hypothesis of I'erimee and Rabin (10) that the
insulin-like actions of GH previously reported (83-84) are only
of pharmacologic, not physiologic, significance.

The increase

in FFA was clearly not due to hypoinsulinemia since insulin levels
actually increased in the GH-infused subjects.

Although this study

did not address the question of the mechanism of this effect,
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results of previous studies,

utilizing pharmacologic doses of GH,

suggest that GH acts directly on the adipocyte to increase lipolysis
in a process that is dependent upon protein and RNA synthesis

(69,73,75,86).

With respect to the role of FFA in the glucose intolerance observed
in this study,

it has been suggested that elevations in circulating

FFA levels may reduce glucose uptake by adipose and muscle tissue
However,

(149).

other studies have found that inhibition of GH-induced

lipolysis either does not prevent

(87)

or only partially prevents

GH-induced deterioration of glucose tolerance.

In this study,

(86)

FFA

levels increased in the 2 subjects who did not exhibit deterioration of
glucose tolerance to the same extent as in the 6 subjects who did
demonstrate decreased glucose tolerance.

It is unlikely,

therefore,

that elevated FFA levels accounted for the changes in glucose tolerance
seen during treatment with GH.
Blood ketone levels also increased during the infusion of GH.
might by secondary to GH-induced FFA elevations leading,
increased delivery of substrate

(FFA)

to the liver.

hypothesis are the findings of Schade and Eaton(150)

in turn,

In support

This
to

of this

that elevations of

blood FFA induced by heparin caused a prompt increase in blood ketone
levels in normal subjects.
vations of Heimberg et al.

Additional support it derived from the obser¬
(151)

that,

in the perfused rat liver, ketone

production is directly proportional to the concentration of FFA in the
perfusate between 0 and 2.5 mM.

Other workers,

however, have presented

evidence to show that increased hepatic delivery of FFA is necessary,
but not sufficient,
(152),

to cause increased hepatic ketone production

McGarry and Foster

(153-154)

to elevated blood FFA levels,
stimulated,

postulated that,

in addition

hepatic ketogenesis must be

possible through the activation of carnitine acyl
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transferase,

the enzyme responsible for transport of fatty acids

to the mitochondrial oxidative pathway.

Furthermore,

that elevations of plasma glucagon levels,
insulin/glucagon ratio,
liver.

In our study,

they suggest

or decreases in the

regulate the ketogenic activity of the

glucagon levels decreased whereas the insulin/

glucagon ratio increased and,

therefore,

for augmenting hepatic ketogenesis.

could not be responsible

Our results do not exclude

a direct effect of GH on hepatic ketogenesis and further studies
will be needed in order to clarify this issue.
this regard,

Of interest in

are studies suggesting that GH may increase ketosis

in insulin-deficient diabetics by stimulating the ketogenic
capacity of the liver and/or by decreasing ketone removal
Regardless of the mechanism involved,

(89).

the elevated blood FFA and

ketone levels induced by GH are consistent with the
that GH is a physiologically significant

possibility

factor in the genesis of

stress-induced elevations of FFA and ketone concentrations.
In man,

pharmacologic doses

amino nitrogen concentrations

of GH cause a decrease

(129-131)

blood levels of several amino acids
after administration of GH.

and a decrease in the

(133) within 30 to 60 minutes

In rats,

increased uptake of many amino acids

lr. hicod

large doses of GH cause
(119-120)

corporation of most amino acids into protein

and increased in¬

(120)

in muscle and

hepatic tissue within 30 to 60 minutes after exposure to GH.
In contrast to this rapid, more generalized effect on amino acid
metabolism,

our data show that physiologic elevations of plasma

GH levels result in a specific decrease in plasma alanine con-
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centrations that is not apparent until 3 hours after initiation
of GH treatment.

We found no evidence of a generalized hypo-

aminoacidemic action of GH which suggests that the results ob¬
served after administration of large doses of GH are a pharma¬
cologic,

not physiologic,

action of GH.

Alanine is of particular importance as the major amino
acid precursor utilized for hepatic gluconeogenesis and in
normal postabsorptive subjects accounts for a minimum of 6%
to 12% of hepatic glucose output

(155).

The glucose-alanine

cycle describes the interorgan transfer of alanine.

In brief,

alanine is synthesized in muscle from glucose- derived pyruvate
by transamination and released into the bloodstream where it is
taken up by the liver and converted into

glucose

(155).

The

observed reduction in plasma alanine levels could be the
result of either a decrease in alanine synthesis and output by
muscle or an increase in herutir alanine uptake.
not distinguish between these possibilities.

Our data do

However,

in a study

in which pharmacologic concentrations of GH were achieved
no effect on hepatic uptake of alanine was observed
it is unlikely that GH-induced changes

(200 ng/ml),

(107).

Thus,

in hepatic alanine uptake

were the cause of the observed decrease in plasma alanine concentra¬
tion.
Insulin is known to lower the blood concentrations of most
amino acids,

particularly the branch

inhibition of their output

chained

from muscle

(156).

ones,

due to an

In contrast,

insulin

tends to increase the output of alanine from muscle due to an in¬
crease in the synthesis of alanine from glucose

(155).

Since no

significant changes in the concentration of other amino acids
were observed in this study and since insulin tends to increase
alanine synthesis in muscle,

it is unlikely that

the decrease in

alanine seen in this study is explained by the elevated plasma
insulin levels in the GH-treated subjects.
It is possible that the decrease in plasma alanine concen¬
tration was not a direct consequence of GH action on amino acid
metabolism.

Sherwin et al#(157)

have shown that

infusion of

ketones for 3 hours into normal postabsorptive subjects results
in a 217

ine in plasma alanine levels without significantly

effecting the concentrations of other amino acids.

The steady

state concentration of ketones achieved in that study is similar
to the concentration observed at the end of the basal period
in the present study.

Alanine was noted to decrease significantly

by 90 minutes after the start of the ketone infusion.
present study,

In the

FFA levels were significantly elevated by 180

minutes, whereas alanine levels did not significantly decrease
until 240 minutes after the start of the GH infusion.

Thus,

our data are consistent with the possibility that the decrease
in plasma alanine may be due to an increase in ketones.

Additions

studies will be needed to determine if the fall in plasma alanine
is a direct effect of GH or a secondary consequence of changes in
other substrates of hormones,

e.g.

ketones.

Our studies indicate that physiologic doses of GH produce
a rapid,

albeit small,

increase in basal insulin concentration

and a marked increase in glucose-stimulated insulin secretion.
Similar findings have previously been reported in situations of
chronic GH excess,

such as acromegaly

(55,57,61-62),

administration of pharmacologic amounts of GH

and after

(62,64-65,106).

Adamson et al,

however,

have reported an acute decrease

in basal and glucose-stimulated insulin secretion after
infusion of physiologic quantities of GH

(109,113-114).

It is difficult to reconcile their findings with our own and
with most of the rest of the literature.
The occurrence of increased FFA and ketone levels
and the deterioration of glucose tolerance in the face of
elevated plasma insulin concentration,

suggests that GH may

have induced a state of insulin resistance.
(53-54,
of GH

63-65)

and acute exposure to pharmacologic doses

(64-65,89)

resistance.

Chronic GH excess

have previously been shown to induce insulin

Our results suggest that GH-induced insulin resis¬

tance can occur rapidly after physiologic elevations of GH
levels.
One possible mechanism of GH-induced insulin resistance is
the presence of changes in the insulin receptor,
like other peptide hormones,

since insulin,

must bind to a specific receptor

on the cell membrane in order to be effective.

The importance

of changes in the receptor is emphasized by the many studies
showing corresponding changes in the insulin receptor and in
insulin sensitivity.

For example,

insulin binding and insulin

sensitivity are both decreased in obesity
onset diabetes

(161—162),

uremia

(162),

(158-160),

and in patients with

idiopathic GH deficiency after treatment with GH
versely,

maturity

(163).

Con¬

insulin sensitivity and insulin binding are both in¬

creased in anorexia nervosa
deficiency

(163).

(164-165)

and in idiopathic GH

This correlation is not universal,

however,

56

since opposite

sensitivity

states

et al.

and increase

found

intake

that 5

days

in affinity of

the

they concluded

insulin actions

at

and

insulin

In rats,

decrease

the hepatocyte

result was normal

a site

(166)

receptor

Kahn

treatment with pharma¬

a slight

insulin levels,

Muggeo et

role

of

insulin

(167).

insulin resistance.

of GH caused

the net

pregnancy

clear exactly what

in GH-induced

(102)

(160),

carbohydrate

is not

cologic doses

Since

occur in binding and

in starvation

of high

It

plays

changes

in number and

insulin receptor.

insulin binding at basal

that

distal

on exerted its

to

the

insulin

anti¬

receptor.

al.(66)

similarly

found a decreased receptor

centration and an

increased

receptor

taken

from acromegalic patients.

normal binding of

and decreased

These

insulin at basal

insulin binding at

affinity

high plasma

levels

might

in part,

of

acromegaly.

with decreased

binding.

Not

least

resulted

to

of

insulin levels.

elevated

(55-61),

all situations

the

the

insulin resistance

GH excess

Patients with anorexia nervosa,

increased insulin binding

The presence

of

increased

fasting and

insulin receptor

insulin sensitivity and decreased

elevated plasma GH levels,

are

associated

insulin

for example,

exhibit

insulin sensitivity and

(164-165).

alterations

in

insulin binding characteristics

and GH excess

do not necessarily

imply

effect

insulin receptor.

Insulin has been shown

on

the

in

insulin concentrations

glucose-stimulated insulin

at

in monocytes

changes

Since many patients with acromegaly have

contribute,

con¬

that

GH exerts

a

direct

to

modulate its own receptor both in vitro (168) and in vivo (169).
Thus, GH could cause decreases in insulin binding by one of
several mechanisms.

It could act directly on the insulin

receptor, it could block insulin action at a site distal to the
receptor, leading, in turn, to hyperinsulineraia and subsequent
insulin-induced receptor changes, or it could directly stimulate
insulin secretion with insulin secondarily modifying the
insulin receptor so as to cause insulin resistance.
In order to see if GH excess acutely effected the insulin
receptor, we measured insulin binding to monocytes and erythro¬
cytes at G and 4 hours after the start of the GH infusion.
This work was done in collaboration with Dr. Vijay Soman.
liminary results are described in Table 7.

Pre¬

They show that

specific binding of insulin to erythrocytes decreased by 16%
(0 hours, 7.7 ± 1.1% vs 4 hours, 6.5 ± 1.0%, p<0.01), whereas
in-uMr, l-’nding to monocytes increased by 45% (0 hours, 10.9 ± 0.9%
VS 4 hours,

15.5 ± 1.6%).

Since only 3 patients were studied, the

monocyte data do not reach statistical significance.

Pre¬

liminary analysis of the binding curves by Dr. Soman suggests
that the decrease in insulin binding to erythrocytes is pri¬
marily due to a decrease in receptor affinity, whereas the
increase in insulin binding to monocytes is mainly due to an
increase in receptor affinity, not receptor number.
While very preliminary,

these results are the first study in

man in which insulin binding was found to decrease in one and
increase in another cell type.

Previous studies have found that

insulin binding to both erythrocytes and monocytes decreases
in maturity onset diabetes (161-162) and increases in anorexia
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nervosa

(164-165).

If further studies confirm these results,

then

the relationship of insulin binding to elements of peripheral blood
to insulin binding on insulin-responsive cells such as adipocytes
and hepatocytes must by carefully examined.

If the monocyte data

is indeed representative of the binding changes on insulin-responsive
tissue,

then it is unlikely that alterations in insulin binding

can account for the observed increase in insulin resistance
induced by acute exposure to physiologic increments of GH.

CONCLUDING STATEMENT

It has been postulated that GH has
effects on glucose and fat metabolism:
effect and 2)

two different types of
1)

an acute insulin-like

an anti-insulin like action seen after longer term

exposure to GH.

Our results suggest that acute elevations of plasma

GH concentrations,

to levels normally seen during severe stress,

do "of ct"se any insulin—like effects and imply that
xnsulin-like actions of GH are a pharmacologic,
Furthermore,

the acute

not physiologic,

effect.

these data show that the anti-insulin actions of GH

can occur within a few hours after exposure to GH.

These findings

are consistent with the possibility that acute elevations of plasma
GH are of physiologic significance in mediating some stress-induced
metabolic changes.
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